NICE estimates that around 300,000 people could be eligible for treatment with Leqvio (inclisiran), and use of the drug will reduce the 10-year risk of a heart attack or death from 29% to 20%.

Novartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by the US regulator last year – and has set a new action date of 1 ...

US President Donald Trump has suspended tariffs on small packages from China, after his sudden order ending duty-free treatment for shipments worth less than $800 (£645) left the US postal ...